Published in J Neurochem on April 01, 2002
The blood-brain barrier: bottleneck in brain drug development. NeuroRx (2005) 5.45
Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab (2012) 2.20
Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Ann Neurol (2012) 2.15
Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets (2009) 1.94
Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol (2010) 1.50
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol (2009) 1.42
B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J Clin Invest (2009) 1.37
Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem (2007) 1.36
Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol (2009) 1.29
The proximal tubule and albuminuria: really! J Am Soc Nephrol (2014) 1.19
Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. Exp Neurol (2007) 1.16
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis (2009) 1.16
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol (2016) 1.08
Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci (2008) 1.04
Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J Biotechnol (2010) 1.04
Investigation of the influence of FcRn on the distribution of IgG to the brain. AAPS J (2009) 1.00
Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy. NeuroRx (2005) 1.00
Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm (2010) 0.99
Brain-reactive antibodies and disease. Annu Rev Immunol (2013) 0.94
Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev (2011) 0.91
Redistribution of the sheep neonatal Fc receptor in the mammary gland around the time of parturition in ewes and its localization in the small intestine of neonatal lambs. Immunology (2002) 0.88
Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β. Brain (2013) 0.88
The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A (2016) 0.87
Expression of neonatal Fc receptor in the eye. Invest Ophthalmol Vis Sci (2014) 0.87
Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice. J Neuroimmune Pharmacol (2008) 0.85
Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int J Cell Biol (2013) 0.85
New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. Front Neurosci (2014) 0.85
The effect of the neonatal Fc receptor on human IgG biodistribution in mice. MAbs (2014) 0.84
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev Clin Pharmacol (2013) 0.84
Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor. MAbs (2014) 0.84
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front Immunol (2015) 0.84
Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood-Brain Barrier. Pharmaceutics (2014) 0.83
Cross-presentation of IgG-containing immune complexes. Cell Mol Life Sci (2012) 0.83
Biologic TNFα-inhibitors that cross the human blood-brain barrier. Bioeng Bugs (2010) 0.82
A novel vascular targeting strategy for brain-derived endothelial cells using a TCR mimic antibody. J Cell Physiol (2010) 0.81
Targeting FcRn for the modulation of antibody dynamics. Mol Immunol (2015) 0.80
Protective effects of an anti-melanocortin-4 receptor scFv derivative in lipopolysaccharide-induced cachexia in rats. J Cachexia Sarcopenia Muscle (2012) 0.79
Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Ther (2014) 0.78
Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus. FASEB J (2015) 0.78
Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation. J Parkinsons Dis (2015) 0.78
Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity. Clin Ophthalmol (2015) 0.77
Influence of molecular size on tissue distribution of antibody fragments. MAbs (2015) 0.77
Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations. Mol Biosyst (2013) 0.77
Interaction of variable bacterial outer membrane lipoproteins with brain endothelium. PLoS One (2010) 0.76
Maternal antibodies and developing blood-brain barrier. Immunol Res (2015) 0.76
Trafficking of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain Barrier. Sci Rep (2016) 0.75
Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts (2016) 0.75
Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice. MAbs (2016) 0.75
Brain antibodies in the cortex and blood of people with schizophrenia and controls. Transl Psychiatry (2017) 0.75
Receptor-mediated transfer of IgG and albumin at cerebrospinal fluid interfaces. J Neural Transm (Vienna) (2015) 0.75
Antibody blood-brain barrier efflux is modulated by glycan modification. Biochim Biophys Acta (2017) 0.75
Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng (2007) 1.44
Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng (2007) 1.42
Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res (2004) 1.42
Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res (2006) 1.40
Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem (2007) 1.36
Neurons express hemoglobin alpha- and beta-chains in rat and human brains. J Comp Neurol (2009) 1.33
Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng (2009) 1.33
Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng (2008) 1.30
Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol (2004) 1.30
Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther (2005) 1.26
Synthesis of pegylated immunonanoparticles. Pharm Res (2002) 1.18
Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther (2003) 1.11
A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics (2012) 1.11
GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol Bioeng (2008) 1.10
Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum Gene Ther (2004) 1.09
AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol (2009) 1.09
Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab Dispos (2009) 1.07
Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther (2002) 1.07
Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res (2007) 1.06
Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med (2002) 1.04
Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J Biotechnol (2010) 1.04
In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med (2003) 1.02
A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease. J Neurophysiol (2011) 1.01
Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med (2004) 1.01
Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther (2002) 1.01
Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab (2002) 1.00
Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther (2003) 1.00
Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm (2010) 0.99
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci (2010) 0.98
Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug Chem (2008) 0.98
Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm (2009) 0.97
Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein. J Cereb Blood Flow Metab (2012) 0.97
Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today (2002) 0.97
Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol Vis (2003) 0.95
Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther (2010) 0.95
Context dependent neuroprotective properties of prion protein (PrP). Prion (2009) 0.95
The blood-brain barrier and neurotherapeutics. NeuroRx (2005) 0.94
Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis-acting regulatory element. J Neurochem (2002) 0.94
Genetic engineering of IgG-glucuronidase fusion proteins. J Drug Target (2010) 0.94
Vascular genomics of the human brain. J Cereb Blood Flow Metab (2002) 0.93
Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metab Dispos (2010) 0.93
Translational science: what is it and why is it so important? Drug Discov Today (2003) 0.93
Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Mol Neurodegener (2012) 0.93
Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res (2010) 0.92
Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur J Neurosci (2012) 0.92
Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J Pharmacol Exp Ther (2011) 0.92
Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm (2009) 0.92
Subtractive expression cloning reveals high expression of CD46 at the blood-brain barrier. J Neuropathol Exp Neurol (2002) 0.91
P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. Neuroreport (2003) 0.91
Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J Drug Target (2002) 0.91
Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem (2013) 0.90
Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab Dispos (2010) 0.90
Rat blood-brain barrier genomics. II. J Cereb Blood Flow Metab (2002) 0.89
Widespread expression of an exogenous gene in the eye after intravenous administration. Invest Ophthalmol Vis Sci (2002) 0.89
Electron microscope study of blood-brain barrier opening induced by immunological targeting of the endothelial barrier antigen. Brain Res (2002) 0.88
Blood-brain barrier disruption following the internal carotid arterial perfusion of alkyl glycerols. J Drug Target (2002) 0.88
Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res (2003) 0.88
Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm Res (2007) 0.88
Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging. Bioconjug Chem (2003) 0.88
Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjug Chem (2010) 0.88
Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. J Nucl Med (2002) 0.88
Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol Pharm (2011) 0.88
Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies. J Drug Target (2012) 0.87
Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy. Pharm Res (2008) 0.87
Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse. Drug Metab Dispos (2011) 0.87
Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein. Drug Metab Dispos (2011) 0.87
Marked enhancement in gene expression by targeting the human insulin receptor. J Gene Med (2003) 0.87
Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease. Brain Res Bull (2012) 0.86
Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng (2011) 0.86
Brain drug development and brain drug targeting. Pharm Res (2007) 0.85
Blood-brain barrier genomics and cloning of a novel organic anion transporter. J Cereb Blood Flow Metab (2007) 0.85
Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnol Bioeng (2012) 0.85
Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J Gene Med (2008) 0.84
Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab Dispos (2012) 0.84
Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells. J Neurochem (2003) 0.84
Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease. Mol Cell Neurosci (2011) 0.84
Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb Protoc (2010) 0.83
Gene therapy of the brain: the trans-vascular approach. Neurology (2004) 0.83
Vascular proteomics and subtractive antibody expression cloning. Mol Cell Proteomics (2002) 0.83
IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol Bioeng (2010) 0.83
Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. Mol Pharm (2010) 0.83
Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein. Pediatr Res (2004) 0.82
Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. Biochim Biophys Acta (2005) 0.82
Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J Gene Med (2004) 0.82
A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics (2014) 0.82
Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. J Neurochem (2003) 0.82
IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm (2009) 0.81
Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. Mol Pharm (2013) 0.81
Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain. Mol Pharm (2010) 0.80
Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein. Brain Res (2010) 0.80
The Ro52/SS-A autoantigen has elevated expression at the brain microvasculature. Neuroreport (2003) 0.80
Log(BB), PS products and in silico models of drug brain penetration. Drug Discov Today (2004) 0.80
Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. Bioconjug Chem (2011) 0.79
The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier. J Drug Deliv (2011) 0.79
IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. Bioconjug Chem (2012) 0.79
Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation. Pharm Res (2006) 0.79